These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent. Doostzadeh J; Clark LN; Bezenek S; Pierson W; Sood PR; Sudhir K Coron Artery Dis; 2010 Jan; 21(1):46-56. PubMed ID: 19952925 [TBL] [Abstract][Full Text] [Related]
4. New DES: a new step forward? Ko BS; Meredith IT Minerva Cardioangiol; 2012 Feb; 60(1):41-56. PubMed ID: 22322573 [TBL] [Abstract][Full Text] [Related]
5. Bioabsorbable drug-eluting stents: the future of coronary angioplasty? Macaya C; Moreno R Nat Clin Pract Cardiovasc Med; 2008 Oct; 5(10):598-9. PubMed ID: 18679382 [TBL] [Abstract][Full Text] [Related]
6. Current and future drug-eluting coronary stent technology. Ielasi A; Latib A; Colombo A Expert Rev Cardiovasc Ther; 2011 Apr; 9(4):485-503. PubMed ID: 21517732 [TBL] [Abstract][Full Text] [Related]
7. Design criteria for the ideal drug-eluting stent. Ako J; Bonneau HN; Honda Y; Fitzgerald PJ Am J Cardiol; 2007 Oct; 100(8B):3M-9M. PubMed ID: 17950830 [TBL] [Abstract][Full Text] [Related]
9. Rationale and study design of the OISTER trial: optical coherence tomography evaluation of stent struts re-endothelialization in patients with non-ST-elevation acute coronary syndromes--a comparison of the intrEpide tRapidil eluting stent vs. taxus drug-eluting stent implantation. Iaccarino D; Politi L; Rossi R; Sgura F; Monopoli D; Modena MG; Sangiorgi GM J Cardiovasc Med (Hagerstown); 2010 Jul; 11(7):536-43. PubMed ID: 20090547 [TBL] [Abstract][Full Text] [Related]
10. Rapid Evaluation of Vessel HEaling After AngiopLasty (REVEAL) trial: rationale, objectives and design. Tamburino C; Capodanno D; La Manna A; di Salvo M; Sanfilippo A; Prati F J Cardiovasc Med (Hagerstown); 2010 Jan; 11(1):53-8. PubMed ID: 19829136 [TBL] [Abstract][Full Text] [Related]
15. A multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: cortisone plus BMS or DES versus BMS alone to eliminate restenosis (CEREA-DES) - study design and rationale. Ribichini F; Tomai F; De Luca G; Boccuzzi G; Presbitero P; Pesarini G; Ferrero V; Ghini AS; Pastori F; De Luca L; Zavalloni D; Soregaroli D; Garbo R; Franchi E; Marino P; Minelli M; Vassanelli C J Cardiovasc Med (Hagerstown); 2009 Feb; 10(2):192-9. PubMed ID: 19377384 [TBL] [Abstract][Full Text] [Related]
16. [Expectation for new-generation drug eluting stents]. Saito S Nihon Rinsho; 2011 Feb; 69(2):237-9. PubMed ID: 21387669 [TBL] [Abstract][Full Text] [Related]
17. Paclitaxel-eluting balloon: from bench to bed. De Labriolle A; Pakala R; Bonello L; Lemesle G; Scheinowitz M; Waksman R Catheter Cardiovasc Interv; 2009 Apr; 73(5):643-52. PubMed ID: 19309715 [TBL] [Abstract][Full Text] [Related]
18. Stent restenosis and thrombosis: etiology, treatment, and outcomes. van Buuren F; Dahm JB; Horskotte D Minerva Med; 2012 Dec; 103(6):503-11. PubMed ID: 23229369 [TBL] [Abstract][Full Text] [Related]
19. Drug-eluting stents: limitations of early generation and progress with newer generation devices. Khattab AA; Windecker S Minerva Med; 2010 Feb; 101(1):9-23. PubMed ID: 20228717 [TBL] [Abstract][Full Text] [Related]
20. Effective and efficient strategies for coronary revascularization in the drug-eluting stent era. Lepor NE; Madyoon H; Kereiakes D Rev Cardiovasc Med; 2002; 3 Suppl 5():S38-50. PubMed ID: 12478234 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]